Inflection Biosciences

Title

Developing new breast cancer therapies

Engagement type

Enterprise Ireland Innovation Voucher

Partner

Inflection Biosciences, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company’s pipeline of highly innovative cancer treatments comprises IBL-202, IBL-300 selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), are currently in pre-clinical stages of development. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards.

Challenge

Inflection Biosciences approached RCSI for assistance in the identification of specific breast cancer patients who may be likely to respond to the company’s therapeutic pipeline.

RCSI value-added

In depth knowledge of current treatment strategies for drug resistant breast cancer and the ability to perform pre-clinical assessment of new compounds targeting that indication.

“We approached Professor Bryan Hennessy and his team at RCSI due to their understanding of where current breast cancer treatments were failing in the clinic and their passion and capability to assess new cancer therapeutics in treating these resistant patient groups. The results from our initial collaboration have identified breast cancer patients who are more likely to respond to our innovative therapeutic approach.”

– Darren Cunningham, Chief Executive Officer, Inflection Biosciences